Basilea News http://www.basilea.com/ Basilea News en Fri, 25 Apr 2014 11:58:03 +0200 Fri, 25 Apr 2014 11:58:03 +0200 Chameleon CMS webmaster@basila.com (Webmaster Webmaster) webmaster@basila.com (Webmaster Webmaster) <![CDATA[Resolutions of the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.]]> http://www.basilea.com/News-and-Media/Resolutions-of-the-Ordinary-General-Meeting-of-Shareholders-of-Basilea-Pharmaceutica-Ltd-/cc8d00b3-808d-a89e-6dc3-eb94c25e2ed1 Wed, 09 Apr 2014 18:36:07 +0200 http://www.basilea.com/News-and-Media/Resolutions-of-the-Ordinary-General-Meeting-of-Shareholders-of-Basilea-Pharmaceutica-Ltd-/cc8d00b3-808d-a89e-6dc3-eb94c25e2ed1 <![CDATA[Basilea's oncology drug candidate BAL101553 demonstrates broad antitumor activity in treatment-resistant breast cancer models as presented at AACR]]> http://www.basilea.com/News-and-Media/Basileas-oncology-drug-candidate-BAL101553-demonstrates-broad-antitumor-activity-in-treatment-resistant-breast-cancer-models-as-presented-at-AACR/b199d358-be2d-fc14-72f7-6ec7bd2fac36 Mon, 07 Apr 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basileas-oncology-drug-candidate-BAL101553-demonstrates-broad-antitumor-activity-in-treatment-resistant-breast-cancer-models-as-presented-at-AACR/b199d358-be2d-fc14-72f7-6ec7bd2fac36 <![CDATA[Basilea swaps its isavuconazole North American co-promote rights for full isavuconazole rights outside of North America]]> http://www.basilea.com/News-and-Media/Basilea-swaps-its-isavuconazole-North-American-co-promote-rights-for-full-isavuconazole-rights-outside-of-North-America/c54f2a5d-f004-4aed-2d5c-d5f26ba841ae Fri, 28 Feb 2014 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-swaps-its-isavuconazole-North-American-co-promote-rights-for-full-isavuconazole-rights-outside-of-North-America/c54f2a5d-f004-4aed-2d5c-d5f26ba841ae <![CDATA[Basilea reports that isavuconazole receives Qualified Infectious Disease Product designation from U.S. FDA for the treatment of invasive mucormycosis]]> http://www.basilea.com/News-and-Media/Basilea-reports-that-isavuconazole-receives-Qualified-Infectious-Disease-Product-designation-from-U-S-FDA-for-the-treatment-of-invasive-mucormycosis/e88516e9-7008-4f5d-aea2-50d7b2168eff Thu, 27 Feb 2014 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-reports-that-isavuconazole-receives-Qualified-Infectious-Disease-Product-designation-from-U-S-FDA-for-the-treatment-of-invasive-mucormycosis/e88516e9-7008-4f5d-aea2-50d7b2168eff <![CDATA[Basilea 2013 full-year results: strong operational and financial performance]]> http://www.basilea.com/News-and-Media/Basilea-2013-full-year-results-strong-operational-and-financial-performance/c20521c0-2282-953b-8dae-9f45eee20902
  • Cash and short-term investments of CHF 274 million
  • Significantly reduced net loss
  • Approval of antibiotic ceftobiprole in Europe
  • Positive phase 3 topline data for antifungal isavuconazole
  • BARDA: Up to 89 million US dollars funding for antibiotic BAL30072
  • ]]>
    Tue, 11 Feb 2014 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-2013-full-year-results-strong-operational-and-financial-performance/c20521c0-2282-953b-8dae-9f45eee20902
    <![CDATA[Basilea reports that isavuconazole receives Qualified Infectious Disease Product (QIDP) designation from U.S. FDA for the treatment of invasive aspergillosis]]> http://www.basilea.com/News-and-Media/Basilea-reports-that-isavuconazole-receives-Qualified-Infectious-Disease-Product-QIDP-designation-from-U-S-FDA-for-the-treatment-of-invasive-aspergillosis/032912a6-c184-ceeb-bbe0-857483bae923 Tue, 03 Dec 2013 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-reports-that-isavuconazole-receives-Qualified-Infectious-Disease-Product-QIDP-designation-from-U-S-FDA-for-the-treatment-of-invasive-aspergillosis/032912a6-c184-ceeb-bbe0-857483bae923 <![CDATA[Basilea reports isavuconazole orphan drug designation for treatment of zygomycosis by U.S. FDA]]> http://www.basilea.com/News-and-Media/Basilea-reports-isavuconazole-orphan-drug-designation-for-treatment-of-zygomycosis-by-U-S-FDA/8be73ced-93e2-4a6d-f61c-1bfd3a3f92a0 Mon, 18 Nov 2013 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-reports-isavuconazole-orphan-drug-designation-for-treatment-of-zygomycosis-by-U-S-FDA/8be73ced-93e2-4a6d-f61c-1bfd3a3f92a0 <![CDATA[Basilea appoints new Chief Financial Officer]]> http://www.basilea.com/News-and-Media/Basilea-appoints-new-Chief-Financial-Officer/028efd07-ee8b-e2e8-4334-2ed4718c6d29 Mon, 04 Nov 2013 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-appoints-new-Chief-Financial-Officer/028efd07-ee8b-e2e8-4334-2ed4718c6d29 <![CDATA[Basilea's antibiotic ceftobiprole obtains regulatory approval in Europe for pneumonia]]> http://www.basilea.com/News-and-Media/Basileas-antibiotic-ceftobiprole-obtains-regulatory-approval-in-Europe-for-pneumonia/d32d8fcb-a9df-6a85-069f-9ef7ed599a8e Wed, 23 Oct 2013 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basileas-antibiotic-ceftobiprole-obtains-regulatory-approval-in-Europe-for-pneumonia/d32d8fcb-a9df-6a85-069f-9ef7ed599a8e <![CDATA[Basilea reports positive topline phase 3 results for antifungal isavuconazole]]> http://www.basilea.com/News-and-Media/Basilea-reports-positive-topline-phase-3-results-for-antifungal-isavuconazole/967f3c8d-ab30-eb6c-ca6a-da36b215e20d
  • Isavuconazole phase 3 invasive aspergillosis study (SECURE) meets primary endpoint
  • ]]>
    Mon, 30 Sep 2013 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-positive-topline-phase-3-results-for-antifungal-isavuconazole/967f3c8d-ab30-eb6c-ca6a-da36b215e20d